Effect of acarbose on blood glucose profiles and plasma 1,5-anhydro-D-glucitol in type 2 diabetes poorly controlled by sulfonylurea therapy

Biomedicine and Pharmacotherapy

Volumn 50, Issue 6-7, 1996, Pages 297-302

  Hotta, N ^a   Koh, N ^a   Sakakibara, F ^a   Naruse, K ^a   Yamada, T ^a   Takeuchi, N ^a   Yamada, K ^b   Fukasawa, H ^c   Kakuta, H ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Inazawa City Hospital   (Japan)

^c Aihoku Hospital   (Japan)

Author keywords

1,5 anhydro D glucitol; Acarbose; Blood glucose profile; Glibenclamide; Type 2 diabetes

Indexed keywords

1,5 ANHYDROSORBITOL; ACARBOSE; FRUCTOSAMINE; GLIBENCLAMIDE; GLUCOSE; MARKER; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; MALE; MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; SINGLE BLIND PROCEDURE;

EID: 0029781809     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/0753-3322(96)84829-3     Document Type: Article

References (25)

1. 1 Alberti KGMM, Gries FA. Management of non-insulin dependent diabetes mellitus in Europe: a consensus view. Diabetic Med 1988;5:275
2. 2 Caspary WF. Sucrose malabsorption in man after ingestion of α-glucosidehydrolase inhibitor. Lancet 1978;i:1231
3. 3 Caspary WF, Graf S. Inhibition of human intestinal α-glucosidehydrolases by a new complex of oligosaccharide. Res Exp Med (Berlin) 1979;175:1
4. 4 Damoiseaux PH, Buysschaert M, Ketelslegers JM, Hillebrand IS, Lambert AE. Effect of acarbose on blood glucose profiles of totally insulin-dependent diabetic patients. Acta Clinica Belgica 1983;38:5
5. 5 Dimitriadis G, Karaiskos C, Raptis S. Effect of prolonged (6 months) α-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus. Horm Metabol Res 1986; 18:253
6. 6 Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulfonylureas in the treatment and metabolic control of diet treated type II diabetic subjects: Two long-term comparative studies. Diabetes Nutr Metab 1990;3(suppl 1):63
7. 7 Gerard J, Luyckx AS, Lefebvre PJ. Improvement of metabolic control in insulin dependent diabetics treated with the α-glucosidase inhibitor acarbose for two months. Diabetologia 1981;21:446
8. 8 Hara T, Nakamura J, Koh N, Sakakibara F, Takeuchi N, Hotta N. An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM. Diabetes Care 1996;19:642
9. 9 Hillebrand I, Boehme K, Frank C, Fink H, Berchtold P. The effects of the α-glucosidase inhibitor BAY g 5421 (acarbose) on meal-stimulated elevations of circulating glucose, insulin, and triglyceride levels in man. Res Exp Med (Berlin) 1979;175:81
10. 10 Holman RR, Steemson J, Turner RC. Sulfonylurea failure in type 2 diabetes: treatment with a basal insulin supplement. Diabetic Med 1987;4:457
11. 11 Hotta N, Kakuta H, Koh N et al. The effect of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Med 1993;10:355
12. 12 Hotta N, Kakuta H, Sano T et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus: a placebo-controlled double-blind study. Diabetic Med 1993;10:134
13. 13 Lebovitz HE, Melander A. Sulfonylureas: basic aspects and clinical uses. In: KGMM Alberti, DeFronzo RA, Keen H, Zimmet P, eds. International Textbook of Diabetes Mellitus, Vol 1. Chichester: John Willey & Sons, 1992:745
14. 14 Lefébvre PJ, Scheen AJ. Update on the treatment of NIDDM. In: PJ Lefébvre, E Standl, eds. New Aspects in Diabetes. Berlin, New York: Walter de Gruyter, 1992:71
15. 15 Marena S, Tagliaferro V, Cavallero G et al. Double-blind crossover study of acarbose in type I diabetic patients. Diabetic Med 1991;8:674
16. 16 Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care 1990;13(suppl 3):32
17. 17 Sachse G, Willims B. Effect of the α-glucosidase inhibitor BAY g 5421 on blood glucose control of sulfonylurea-treated diabetics and insulin-treated diabetics. Diabetologia 1979;17:287
18. 18 Schlichtkrull J, Munck O, Jersild M. The M-value, an index of blood-sugar control in diabetics. Acta Med Scand 1965;177:95
19. 19 Schmidt DD, Frommer W, Junge B, Muller L, Wingender W, Truscheit E. α-Glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 1977;64:535
20. 20 Stout RW. Diabetes and atherosclerosis - The role of insulin. Diabetologia 1979;16:141
21. 21 Tuomilehto I. Acarbose monotherapy in the treatment of non-insulin-dependent diabetes mellitus - a review. In: Creutzfeldt W, ed. Acarbose for the Treatment of Diabetes Mellitus. Berlin: Springer-Verlag, 1988:104
22. 22 Turner RC, Holman RR, Mathews DR. Sulfonylurea failure and inadequacy. In: Cameron D, Colagiuri S, Heding L, Kuhl C, Ma A, Mortimer R, eds. Non-insulin Dependent Diabetes Mellitus. Hong Kong: Excepta Medica, 1989:52
23. 23 Walton RJ, Sherif IT, Noy GA, Alberti KGMM. Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor. Br Med J 1979; 1:220
24. 1c and fructosamine for detection of diabetes mellitus. Diabetes 1991;40:52
25. 25 Yamanouchi T, Minoda S, Yabuuchi M et al. Plasma 1,5-anhydro-D-glucitol as a new clinical marker of glycemic control in NIDDM patients. Diabetes 1989;38:723